Gut bacterial profiles in Parkinson's disease: A systematic review.
Gut bacterial profiles in Parkinson's disease: A systematic review.
复制标题
帕金森病的肠道细菌特征：系统评价
DOI：
10.1111/cns.13990
复制
发表时间：
2023-01
影响因子：
5.5
通讯作者：
中科院分区：
文献类型：
--
作者：
最近的进展突出了肠道生态失调和帕金森病（PD）之间的关系。从PD患者到小鼠的微生物群移植可诱导α-突触核蛋白介导的运动缺陷增加。人体研究已经确定了PD患者与健康对照组相比肠道微生物群的差异。我们进行了一项系统性综述，以评估肠道细菌参与PD病因学的现有证据。从一开始到2021年6月，检索了PubMed数据库、中国国家知识基础设施数据库和万方数据，以确定调查PD与粪便中定量微生物群之间关系的人类病例对照研究。我们评估了由此产生的研究，重点是PD患者和健康对照之间不同的细菌分类群。在26项研究中，53个微生物家族和98个属在PD患者和健康对照之间表现出差异。两项以上研究确定的PD增加的属为双歧杆菌属、Alistipes、Christensenella、肠球菌属、颤螺旋菌属、嗜胆汁菌属、脱硫弧菌属、埃希氏菌/志贺氏菌属和阿克曼氏菌属，而普雷沃菌属、布劳特氏菌属、粪杆菌属、梭形杆菌属和嗜血杆菌属有三项或更多报告在PD患者中较低。不止一份报告表明，拟杆菌属、气味杆菌属、副拟杆菌属、丁酸球菌属、丁酸弧菌属、梭菌属、粪球菌属、毛螺菌属、乳杆菌属、巨球菌属、乳杆菌属、罗斯拜瑞氏菌属、瘤胃球菌属、链球菌属和克雷伯氏菌属在两个方向上发生了改变。我们的综述表明，肠道微生物组在PD病因学中的参与可能涉及短链脂肪酸（SCFAs）产生细菌的改变和推定的肠道致病菌的增加。产生SCFAs的细菌可能高于或低于“最佳范围”，导致不平衡。考虑到双歧杆菌、乳杆菌和阿克曼氏菌对人类健康有益，PD肠道微生物组中双歧杆菌和乳杆菌的增加可能与PD药物相关，尤其是COMT抑制剂，而高水平的阿克曼氏菌可能与衰老相关。肠道细菌与帕金森病（PD）相关的作用可能涉及具有产生短链脂肪酸（SCFA）能力的细菌的改变和推定致病菌的增加，这可能共同作用，可能损害肠道屏障和/或血脑屏障的完整性，刺激全身和神经炎症。产生SCFAs的细菌可能会在“最佳范围”之外减少或增加。考虑到双歧杆菌、乳杆菌和阿克曼氏菌对人体健康有益，双歧杆菌和乳杆菌的增加可能与PD药物，特别是COMT抑制剂有关，而阿克曼氏菌的高水平可能与衰老有关。
Recent advances have highlighted the relationships between gut dysbiosis and Parkinson's disease (PD). Microbiota transplantation from PD patients to mice can induce increased alpha‐synuclein‐mediated motor deficits. Human studies have identified differences in the gut microbiota of PD patients compared to healthy controls. We undertook a systematic review to evaluate the available evidence for the involvement of gut bacteria in the etiology of PD. The PubMed databank, the China National Knowledge Infrastructure databank, and Wanfang Data were searched from inception until June 2021 to identify human case–control studies that investigated relationships between PD and microbiota quantified from feces. We evaluated the resulting studies focusing on bacterial taxa that were different between PD patients and healthy controls. Twenty‐six studies were found in which 53 microbial families and 98 genera exhibited differences between patients with PD and healthy controls. The genera identified by more than two studies as increased in PD were Bifidobacterium, Alistipes, Christensenella, Enterococcus, Oscillospira, Bilophila, Desulfovibrio, Escherichia/Shigella, and Akkermansia, while Prevotella, Blautia, Faecalibacterium, Fusicatenibacter, and Haemophilus had three or more reports of being lower in PD patients. More than one report demonstrated that Bacteroides, Odoribacter, Parabacteroides, Butyricicoccus, Butyrivibrio, Clostridium, Coprococcus, Lachnospira, Lactobacillus, Megasphaera, Phascolarctobacterium, Roseburia, Ruminococcus, Streptococcus, and Klebsiella were altered in both directions. Our review shows that the involvement of the gut microbiome in the etiology of PD may involve alterations of short‐chain fatty acids (SCFAs)‐producing bacteria and an increase in putative gut pathobionts. SCFAs‐producing bacteria may vary above or below an “optimal range,” causing imbalances. Considering that Bifidobacterium, Lactobacillus, and Akkermansia are beneficial for human health, increased Bifidobacterium and Lactobacillus in the PD gut microbiome may be associated with PD medications, especially COMT inhibitors, while a high level of Akkermansia may be associated with aging. The role of gut bacteria in association with Parkinson's disease (PD) may involve the alterations of bacteria with the capacity to produce short‐chain fatty acids (SCFAs) and an increase in putative pathobionts, which may work together to potentially impair the intestinal barrier and/or blood–brain barrier integrity, stimulating systemic and neural inflammation. SCFAs‐producing bacteria may reduce or increase outside of an “optimal range”. Considering that Bifidobacterium, Lactobacillus, and Akkermansia are beneficial for human health, the increased Bifidobacterium and Lactobacillus may be associated with PD medications, especially COMT inhibitors, while a high level of Akkermansia may be associated with aging.
登录
查看更多内容
DOI：
10.1002/mds.27105
发表时间：
2018-01
期刊：
Movement disorders : official journal of the Movement Disorder Society
影响因子：
--
作者：
Heintz-Buschart A;Pandey U;Wicke T;Sixel-Döring F;Janzen A;Sittig-Wiegand E;Trenkwalder C;Oertel WH;Mollenhauer B;Wilmes P
通讯作者：
Wilmes P
影响因子：
4.5
作者：
Abuqwider JN;Mauriello G;Altamimi M
通讯作者：
Altamimi M
影响因子：
5.9
作者：
Badal VD;Vaccariello ED;Murray ER;Yu KE;Knight R;Jeste DV;Nguyen TT
通讯作者：
Nguyen TT
肠道微生物群：健康和疾病的整体调节因素
影响因子：
5.2
作者：
Feng Q;Chen WD;Wang YD
通讯作者：
Wang YD
影响因子：
12.2
作者：
Agudelo-Ochoa GM;Valdés-Duque BE;Giraldo-Giraldo NA;Jaillier-Ramírez AM;Giraldo-Villa A;Acevedo-Castaño I;Yepes-Molina MA;Barbosa-Barbosa J;Benítez-Paéz A
通讯作者：
Benítez-Paéz A